量化临床前阿尔茨海默病中的推定视网膜胶质增生
本研究用en face光学相干断层扫描(OCT)比较临床前阿尔茨海默病(AD)患者与对照组推定视网膜胶质增生面积及视网膜神经纤维层(RNFL)厚度。结果显示临床前AD组推定视网膜胶质增生面积显著大于对照组,而9个ETDRS分区RNFL厚度组间无显著差异。作者认为推定视网膜胶质增生可能是AD相关神经炎症的潜在生物标志物。
要点
- 临床前AD组推定视网膜胶质增生面积0.97±0.55 mm²,显著大于对照组0.68±0.40 mm²(P=0.039,Cohen's d=0.61)。
- 9个ETDRS分区RNFL厚度在临床前AD组与对照组间均无显著差异(P>0.05)。
- 作者认为推定视网膜胶质增生可能是AD相关神经炎症的潜在生物标志物。
核心结论
- 分析显示临床前AD患者推定视网膜胶质增生面积大于对照组,作者认为其可能是AD相关神经炎症的潜在生物标志物。
研究设计与样本
- 使用Spectralis II采集76名参与者(132眼)黄斑中心20×20度和30×25度光谱域OCT图像。
- 纳入22例临床前AD患者(40眼,平均年龄69岁,范围60-80岁)和20名对照(32眼,平均年龄66岁,范围58-82岁,P=0.11)评估推定视网膜胶质增生面积与RNFL厚度差异。
- 采用广义线性混合模型比较两组ETDRS图9个分区的推定视网膜胶质增生面积和RNFL厚度。
主要发现
- 临床前AD组推定视网膜胶质增生面积为0.97±0.55 mm²,对照组为0.68±0.40 mm²,组间差异显著(F(1,70)=4.41,P=0.039,Cohen's d=0.61)。
- 9个ETDRS分区RNFL厚度组间均无显著差异(P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neuroinflammation plays a significant role in the pathology of Alzheimer's disease (AD). Mouse models of AD and postmortem biopsy of patients with AD reveal retinal glial activation comparable to central nervous system immunoreactivity. We hypothesized that the surface area of putative retinal gliosis observed in vivo using en face optical coherence tomography (OCT) imaging will be larger in patients with preclinical AD versus controls. METHODS: The Spectralis II instrument was used to acquire macular centered 20 × 20 and 30 × 25-degrees spectral domain OCT images of 76 participants (132 eyes). A cohort of 22 patients with preclinical AD (40 eyes, mean age = 69 years, range = 60-80 years) and 20 control participants (32 eyes, mean age = 66 years, range = 58-82 years, P = 0.11) were included for the assessment of difference in surface area of putative retinal gliosis and retinal nerve fiber layer (RNFL) thickness. The surface area of putative retinal gliosis and RNFL thickness for the nine sectors of the Early Treatment Diabetic Retinopathy Study (ETDRS) map were compared between groups using generalized linear mixed models. RESULTS: The surface area of putative retinal gliosis was significantly greater in the preclinical AD group (0.97 ± 0.55 mm2) compared to controls (0.68 ± 0.40 mm2); F(1,70) = 4.41, P = 0.039; Cohen's d = 0.61. There was no significant difference between groups for RNFL thickness in the 9 ETDRS sectors, P > 0.05. CONCLUSIONS: Our analysis shows greater putative retinal gliosis in preclinical AD compared to controls. This demonstrates putative retinal gliosis as a potential biomarker for AD-related neuroinflammation.
引用
- Ravichandran S, Snyder PJ, Alber J, et al. Quantifying Putative Retinal Gliosis in Preclinical Alzheimer's Disease. Invest Ophthalmol Vis Sci. 2024. PMID: 38696189. doi:10.1167/iovs.65.5.5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。